# Early Markers of Disease and Response to Therapy

> **NCT04118153** · EARLY_PHASE1 · COMPLETED · sponsor: **Sandra Lord, MD** · enrollment: 60 (actual)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DRUG:** Abatacept

## Key facts

- **NCT ID:** NCT04118153
- **Lead sponsor:** Sandra Lord, MD
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-05
- **Primary completion:** 2024-05-24
- **Final completion:** 2024-05-24
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-06-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04118153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04118153, "Early Markers of Disease and Response to Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04118153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*